Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy

AIDS Patient Care and STDs

Volumn 22, Issue 10, 2008, Pages 779-786

  Diehl, Leandro A ^a   Fabris, Bruno A ^a   Barbosa, Décio S ^a   De Faria, Eliana C ^b   Wiechmann, Susana L ^a   Carrilho, Alexandre J F ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CREATININE; GLIFAGE; GLUCOSE; HIGH DENSITY LIPOPROTEIN 3; INSULIN; LACTIC ACID; LIPID; METFORMIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT DISTRIBUTION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIARRHEA; DYSGEUSIA; DYSPEPSIA; EVENING DOSAGE; FAT LOSS; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; MALE; MICROULTRACENTRIFUGATION; MORNING DOSAGE; NAUSEA; SIDE EFFECT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BODY FAT DISTRIBUTION; CHOLESTEROL, HDL; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 53849130997     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0012     Document Type: Article

References (50)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
2. Behrens GMN, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003;17(Suppl 1):S149-S154.
3. Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 2006;184:72-77.
4. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41-46.
5. van Wijk JPH, de Koning EJP, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med 2005;143:337-346.
6. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy. Ann Intern Med 2004;140:786-794.
7. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-4615.
8. Sodré FL, Castanho VS, Castilho LN, de Barros-Mazon S, de Faria EC. High-density lipoprotein subfractions in normolipidemic individuals without clinical atherosclerosis lipoprotein subfractions in an adult population. J Clin Lab Anal 2006;20:113-117.
9. The Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM)-Diabetes Trials Unit. HOMA2 Calculator for Excel [software]. www.dtu.ox.ac.uk/index.php?maindoc=/homa/index.php (Last accessed January 1, 2007).
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
11. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Circulation 2002;22:667-673.
12. Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci 2005;330:295-302.
13. Albers JJ, Aladjem F. Precipitation of 125-I-labeled lipoproteins with specific polypeptide antisera: Evidence for two populations with differing polypeptide compositions in human high density lipoproteins. Biochemistry 1971;10:3436-3442.
14. Syvänne M, Ahola M, Lahdenperä S, et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573-582.
15. Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-1069.
16. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462.
17. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-1504.
18. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naãve cohort. HIV Med 2005;6:114-121.
19. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
20. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscl Thromb Vasc Biol 2000;20:2670-2676.
21. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes 1997;20:1087-1092.
22. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-477.
23. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007;21:47-57.
24. Coll B, van Wijk JPH, Parra S, et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006;544:104-110.
25. Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 2007;8:420-426.
26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
27. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192.
28. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109(Suppl 3):8-14.
29. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994;5:404-416.
30. Falutz J. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007;3:651-661.
31. Barlage S, Fröhlich D, Böttcher A, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001;42:281-290.
32. Khovidhunkig W, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin:cholesterol acyltransferase. J Lipid Res 2001;42:967-975.
33. Skretting G, Gjernes E, Prydz H. Regulation of lecithin:cholesterol acyltransferase by TGF-beta and interleukin-6. Biochim Biophys Acta 1995;1255:267-272.
34. Kwong LK, Ridinger DN, Bandhauer M, et al. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesterol acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J Clin Endocrinol Metab 1997;82:1527-1581.
35. Diamanti-Kandarakis D, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reproduct 2006;21:1426-1431.
36. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-3394.
37. Anurag P, Anuradha CV. Metformin improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diab Obes Metab 2002;4:36-42.
38. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
39. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions and the risk of acute myocardial infarction: A prospective population study in eastern Finnish men. Circulation 1991;84:129-139.
40. 3 cholesterol subfractions with the development of ischemic heart disease in British men: The Caerphilly and Speedwell Collaborative Heart Disease studies. Circulation 1994;90:769-774.
41. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J-P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Arterioscl Thromb Vasc Biol 1997;17:1098-1105.
42. Asztalos BF, Collins D, Cupples A, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185-2191.
43. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscl Thromb Vasc Biol 2003;23:1881-1888.
44. Lamarche B, Rachid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999;286:145-161.
45. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98.
46. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-1585.
47. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocrine Rev 2000;21:697-738.
48. Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2003;87:4845-4856.
49. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care and STDs. 2007;21:452-457.
50. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and fat resistance. J Clin Endocrinol Metab 2001;86:939-943.